Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy
Liver International · 2025
DOI: 10.1111/liv.70264 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Marta Fortuny und 28 weiteren Autor:innen. Beteiligte Einrichtung: Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona Clinic Liver Cancer (BCLC) Group, Barcelona, Spain. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Immunotherapy, Intensive Care Units, Liver Cirrhosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Fundación Científica Asociación Española Contra el Cáncer.
Themen: Intensivpflege
Abstract (Originalsprache)
Background and Aims Intensive Care Unit (ICU) admission is usually denied to patients with advanced hepatocellular carcinoma (HCC) due to the perceived poor prognosis associated with both cirrhosis and liver cancer. However, immunotherapy based on immune checkpoint inhibitors (ICI) has transformed the treatment landscape, and the role of critical care is becoming more relevant in managing adverse events. We aim to assess the outcome of patients with advanced HCC treated with ICI admitted to the ICU.
Methods
We evaluated patients treated with ICI combinations across 20 medical centres globally between November 2012 and April 2024. Demographic data, ICI types, causes of admission, organ support, and mortality in the short and medium term were recorded.
Results
Of 1065 patients, 47 (4.4%) were admitted to the ICU. Most were male (76.6%) with cirrhosis (93.6%), and 59.7% received ICI as first‐line therapy. The primary reasons for ICU admission were immune‐related adverse events (irAE) in 46.8% and variceal bleeding in 29.8%. The median time to ICU admission was 115 days [IQR 38–202] after the initiation of ICI treatment. Among patients admitted due to irAEs, the median time was 51 days [IQR 31–137]. ICU mortality was 25.5%. Two‐thirds were alive 28 days post‐ICU discharge, with 3‐ and 6‐month survival rates of 83% and 69%. Of the 61.3% of survivors, they were rechallenged with ICI or started new HCC therapy. Conclusions irAEs are the main cause of ICU admission in patients with advanced HCC receiving ICI. Despite the severity, 66% were discharged, and nearly half resumed treatment. These findings highlight the vital role of ICU care in managing HCC patients, challenging the notion of denying them intensive care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona Clinic Liver Cancer (BCLC) Group, Barcelona, Spain.
- Liver Oncology Unit, Liver Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
- Oncologia Médica, Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, Sao Paulo, Brazil.
- Service d'Hépato-Gastroentérologie, Unité d'Hépatologie Généralt, Groupe Hospitalier Pitié-Salpétrière, Paris, France.
- Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain.
ORCID-Profile: Marta Fortuny, Leonardo G da Fonseca, Manon Allaire, Jean-Charles Nault, Massimo Iavarone, Sofia Ridolfo, Sonia Pascual, Marco Sanduzzi-Zamparelli, Tania Hernaez, Alberto Lue, María Varela, Javier Fernández
Förderung
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
- Instituto de Salud Carlos III
- Fundación Científica Asociación Española Contra el Cáncer
Zitieren
APA
Fortuny, M., da Fonseca, L. G., Allaire, M., Sánchez, R., Nault, J. C., Iavarone, M., Ridolfo, S., Pascual, S., Jimeno, R., Calvo, M., Rifà, R., Sanduzzi-Zamparelli, M., Jiménez-Esquivel, N., Mouri, S., Iñarrairaegui, M., Argemi, J., Hernaez, T., Lorenzo-Barreto, J. E., Ferrer, M. T., …, & Reig, M. (2025). Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy. Liver International. https://doi.org/10.1111/liv.70264
Vancouver
Fortuny M, da Fonseca LG, Allaire M, Sánchez R, Nault JC, Iavarone M, et al. Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy. Liver International. 2025. doi:10.1111/liv.70264
BibTeX
@article{Fortuny2025,
author = {Fortuny, Marta and da Fonseca, Leonardo G and Allaire, Manon and Sánchez, Rocío and Nault, Jean-Charles and Iavarone, Massimo and Ridolfo, Sofia and Pascual, Sonia and Jimeno, Raquel and Calvo, Mariona and Rifà, Raimon and Sanduzzi-Zamparelli, Marco and Jiménez-Esquivel, Natalia and Mouri, Sarah and Iñarrairaegui, Mercedes and Argemi, Josepmaria and Hernaez, Tania and Lorenzo-Barreto, José Enrique and Ferrer, María Teresa and Coll, Susana and Lamarca, Ángela and Marin, Juan Ignacio and Reverter, Enric and López, Ana María and Lue, Alberto and Varela, María and Matilla, Ana and Fernández, Javier and Reig, Maria},
title = {Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70264}
}
EUVIMED